Phio Pharmaceuticals Corp.
General ticker "PHIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.9M (TTM average)
Phio Pharmaceuticals Corp. follows the US Stock Market performance with the rate: 7.6%.
Estimated limits based on current volatility of 4.3%: low 1.22$, high 1.33$
Factors to consider:
- Total employees count: 9 (0.0%) as of 2023
- Top business risk factors: Dependence on INTASYL technology, Market competition, Economic downturns and volatility, Labor/talent shortage/retention, Regulatory and compliance
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.45$, 4.71$]
- 2025-12-31 to 2026-12-31 estimated range: [1.01$, 3.31$]
Financial Metrics affecting the PHIO estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -44.76 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 82.31 > 63.39
- Positive: Investing cash flow per share per price, % of 0.05 > -0.66
Short-term PHIO quotes
Long-term PHIO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $11.46MM | $10.82MM | $7.39MM |
| Operating Income | $-11.46MM | $-10.82MM | $-7.39MM |
| Non-Operating Income | $-0.02MM | $-0.00MM | $0.24MM |
| R&D Expense | $7.01MM | $6.33MM | $3.64MM |
| Income(Loss) | $-11.48MM | $-10.83MM | $-7.15MM |
| Profit(Loss)* | $-11.48MM | $-10.83MM | $-7.15MM |
| Stockholders Equity | $10.84MM | $7.73MM | $4.72MM |
| Assets | $12.81MM | $9.36MM | $5.74MM |
| Operating Cash Flow | $-12.13MM | $-10.75MM | $-7.11MM |
| Capital expenditure | $0.12MM | $0.01MM | $0.00MM |
| Investing Cash Flow | $-0.12MM | $-0.01MM | $0.01MM |
| Financing Cash Flow | $-0.03MM | $7.41MM | $4.00MM |
| Earnings Per Share** | $-91.00 | $-46.87 | $-0.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.